A scientific alliance is taking on the challenge of developing pediatric HIV medications, the Inter Press Service (IPS) reports. The nonprofit Drugs for Neglected Diseases Initiative (DNDI) hopes to have new formulations of antiretroviral (ARV) meds for children younger than 3 on the market between 2014 and 2016. Since mother-to-child transmission of HIV has been drastically cut in the developed world, DNDI asserts that child-adapted ARVs are not a priority for pharmaceutical companies. To meet that need, DNDI is working with both public and private sector partners in the developing world.
To read the IPS article, click here.